Research Cluster

Vision, Ocular Health & Neuroprotection Peptides

The eye is, pharmacologically speaking, a privileged organ with unusual challenges and unusual opportunities. The blood-retinal barrier and blood-aqueous barrier restrict systemic drug delivery to ocular targets, which makes local administration—intravitreal, topical, subconjunctival—the dominant delivery strategy for most ocular indications. Peptides are well-suited to this context: they are too large to cross the blood-retinal barrier systemically, which makes local delivery the natural route, and many of the most important ocular biology signals are neuropeptides and neurotrophic factors that act on the densely innervated cornea, trabecular meshwork, and retina.

The therapeutic landscape here is defined by the conditions with unmet need: neurotrophic keratitis (corneal denervation), dry eye disease, diabetic retinopathy, age-related macular degeneration, glaucoma, and uveitis. The anti-VEGF revolution in retinal disease—ranibizumab, bevacizumab, aflibercept—demonstrated that targeted biologic delivery to the vitreous is clinically feasible and commercially transformative. Peptide therapeutics in this cluster occupy a related space: neurotrophic support and anti-inflammatory modulation rather than anti-angiogenic blockade, and in several cases address conditions the anti-VEGF drugs don’t touch.

One approved drug. Three active Phase II programs. A broader preclinical landscape that has not translated to late-stage development at the same pace as retinal anti-VEGF biologics.

Cluster at a Glance

9 compounds • 1 FDA-approved (neurotrophic keratitis) • 4 Phase II programs • 2 pilot/limited human data • 2 preclinical only • Delivery route matters critically: topical vs. intravitreal vs. subconjunctival applications documented separately

Evidence Tiers:
Approved Drug
Clinical Trials
Pilot / Human Data
Preclinical Only

Route of Administration in Ocular Peptide Therapy

Delivery route is clinically determinative in this cluster in a way that is less true for systemic peptide applications. Topical eye drops reach the cornea and conjunctiva reliably but deliver negligible amounts to the posterior segment. Intravitreal injection reaches the vitreous, retina, and choroid directly but bypasses the anterior segment. Subconjunctival and periocular delivery is intermediate. Where evidence from one route exists, it does not automatically validate another route for the same compound—this distinction is applied to every card in this cluster.

⚠  Intravitreal Injection Is a Surgical Procedure. It Is Not a Self-Experimentation Route.

This needs to be said plainly, because the self-experimentation community that engages with this site has shown it will attempt almost anything with a syringe. Intravitreal injection—delivering a compound directly into the vitreous humor of the eye—is performed by trained ophthalmologists in sterile clinical settings under direct visualization, using calibrated needles, sterile technique, and immediate post-procedure monitoring for raised intraocular pressure, retinal detachment, vitreous hemorrhage, and endophthalmitis. Endophthalmitis is a bacterial infection inside the eye. It can and does cause permanent blindness. It can occur even when the procedure is performed correctly by an ophthalmologist in a surgical suite. The clinical trial data for somatostatin analogs and other intravitreal compounds in this cluster exists because those trials were conducted by ophthalmologists in hospitals. That data does not mean intravitreal self-injection is a logical next step. It means ophthalmologists ran trials. There is no version of this where injecting a research peptide into your own eye at home is a reasonable risk calculation. If you are considering this: stop. This is the one application on this entire site where the potential harm is immediate, irreversible, and not proportionate to any plausible benefit.

How These Compounds Relate

The compounds in this cluster address four distinct pathological processes in the eye: corneal denervation and neurotrophic keratitis (cenegermin, thymosin beta-4/RGN-259, SP+IGF-1 combination); intraocular inflammation and uveitis (PL-8177); retinal neovascularization and diabetic retinopathy (somatostatin analogs, anti-VEGF peptide fragments); and retinal and corneal neuroprotection in degenerative or ischemic disease (humanin, BPC-157). These four disease contexts require different delivery routes, different cellular targets, and different pharmacological strategies—the unifying feature is the ocular anatomy, not a shared receptor family or mechanism.

The cenegermin approval is the landmark event for this cluster. It established that recombinant peptide drugs can be delivered topically to the ocular surface in a 6-times-daily regimen, achieve therapeutic tissue concentrations, and pass regulatory review for a rare but serious ophthalmological indication. The REPARO trial design—randomized, double-masked, vehicle-controlled, with objective corneal healing as the primary endpoint—is the methodological reference for what a rigorous ocular peptide trial looks like. RGN-259 and the SP+IGF-1 program are working in the same neurotrophic keratitis and dry eye space with smaller trial designs.

The somatostatin analog diabetic retinopathy program is the most pharmacologically specific crossover in this cluster: intravitreal octreotide and lanreotide are using the same SSTR2 pharmacology as the systemically approved drugs, but delivered locally to a retinal target that cannot be reached in therapeutic concentrations by systemic administration. This is the same delivery logic as local scalp IGF-1 in the hair cluster—local delivery addresses a tissue-specific deficiency or target that systemic dosing cannot reach selectively.

Humanin’s presence in this cluster illustrates a broader principle: several compounds whose primary documented biology is systemic neuroprotection or longevity have specific retinal expressions with direct relevance to ophthalmic disease. The retina is CNS tissue—the only CNS tissue directly accessible to clinical observation—and the neuroprotective peptide biology of humanin, NGF, and somatostatin is not separate from ocular biology. It is continuous with it.

Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation. Eye conditions require evaluation and treatment by a qualified ophthalmologist or optometrist. Do not use any compound discussed here in or near the eye without professional medical supervision.

Scroll to Top